Goldman Sachs Starts Rocket Pharmaceuticals (RCKT) at Neutral, 'Four Potential Launches in Next 2Y but DD Oppy May be Overstated'
Tweet Send to a Friend
(Updated - April 2, 2024 3:42 AM EDT)
Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
